Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
C-type lectin domain family 2 member B (CLEC2B)
- Target
- CLEC2B
- Molecular classification
- C-type lectin-like domain protein, Cell surface receptor (ligand), Type 2 transmembrane protein
01
Overview
C-type lectin domain family 2 member B (CLEC2B) is a type 2 transmembrane protein encoded by the CLEC2B gene in humans. It belongs to the C-type lectin/C-type lectin-like domain superfamily, found predominantly in lymphoid tissues and hematopoietic cell types. CLEC2B functions as a cell activation antigen involved in cell adhesion, signaling, and glycoprotein turnover as well as mediating inflammatory and immune responses. Its main known ligand interaction is with the natural killer cell receptor NKp80 (KLRF1), participating in the activation of NK cells and possibly contributing to innate immunity and immunopathology within the tumor microenvironment or in the context of infection[1][2][7]. No approved therapeutics are known to directly target CLEC2B at this time.
- Other names
- C-type lectin domain family 2 member BCLEC2BActivation-induced C-type lectinCLECSF2IFNRG1AICLHP10085C-type lectin superfamily member 2IFN-alpha-2b-inducing-related protein 1
02
Mechanism of action
Modulation of immune cell activation via interaction with NKp80 (KLRF1) receptor on natural killer cells[7]
03
Biological functions
Cell activation antigenCell adhesionCell-cell signalingGlycoprotein turnoverImmune responseInflammation
04
Disease associations
InflammationInfectionImmune-related disordersCancer (expressed in hematopoietic and lymphoid tissues, sometimes relevant in tumor microenvironment)
05
Safety considerations
Immunomodulation may carry risks of immune dysregulation or excessive inflammation if targeted; safety profile unknown due to absence of clinical compounds targeting this molecule[6]
06
Biomarkers
CLEC2B expression in lymphoid tissues and hematopoietic cells may serve as a biomarker for immune cell activation or inflammation[2][7]
Beyond the preview
Go deeper on C-type lectin domain family 2 member B (CLEC2B).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on C-type lectin domain family 2 member B (CLEC2B).